Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
AXDXAccelerate Diagnostics(AXDX) Zacks Investment Research·2024-05-09 07:26

Accelerate Diagnostics (AXDX) came out with a quarterly loss of 0.88pershareversustheZacksConsensusEstimateofalossof0.88 per share versus the Zacks Consensus Estimate of a loss of 0.72. This compares to loss of 1.70pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−22.221.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of 0.62 per share when it actually produced a loss of $0.89, delivering a surprise of -4 ...